Shanghai Bio-heart Biological Technology Co., Ltd. announced that at EuroPCR 2022, which is an official annual meeting of the European Association of Percutaneous Cardiovascular Interventions, the Company finalized plans with clinical trial investigators on the European clinical trial on Renal Artery Denervation Using Radial Access in Uncontrolled Hypertension . The European Cardiovascular Research Center ("CERC") will conduct the RADIUS-HTN Trial and evaluate the Company's Iberis 2nd transradial renal denervation (RDN) system in patients with uncontrolled hypertension. The RADIUS-HTN Trial will compare the effectiveness of renal denervation performed via transradial arterial access (TRA) and transfemoral arterial access (TFA).

The principal investigator for the RADIUS-HTN Trial is Professor Felix Mahfoud, MD from Saarland University Hospital, Homburg/Saar and chairman of the Arterial Hypertension Working Group of the German Cardiac Society.